Abstract
Background/aim Erythema nodosum (EN) is an inflammatory disorder of subcutaneous tissue. Although etiopathogenesis of the disease is unknown, many predisposing factors such as infections, systemic disease, and drugs have been identified. Neutrophil to lymphocyte ratio (NLR) has been shown to be a novel inflammatory marker in many dermatological diseases. The aim of our study is to investigate NLR in EN patients and evaluate its relation to the underlying cause of the disease.Materials and methods Between 2014 and 2018, clinical and laboratory data of 395 patients diagnosed with EN and 395 controls were extracted from patient files. EN patients were grouped as idiopathic EN and secondary EN (EN with an identified underlying cause). Clinical and laboratory characteristics of the two groups were compared. Results NLR was elevated in EN patients compared to controls (median of 2.38 vs. 1.55, P < 0.001). Among EN patients, NLR was also elevated in patients with secondary EN. In multivariate logistic regression model NLR (> 2.11), RDW-CV (> 13.65), and CRP (> 5.5) were identified as risk factors for secondary EN (relative risks were 17.16, 2.69, and 2, respectively). Conclusion Elevated NLR (> 2.11) may be used as a parameter to discriminate secondary EN from idiopathic EN.
Highlights
Erythema nodosum (EN) is an inflammatory disorder of subcutaneous tissue characterized by erythematous, tender subcutaneous nodules predominantly affecting lower extremities
Neutrophil to lymphocyte ratio (NLR) was elevated in EN patients compared to controls
Among EN patients, NLR was elevated in patients with secondary EN
Summary
Erythema nodosum (EN) is an inflammatory disorder of subcutaneous tissue characterized by erythematous, tender subcutaneous nodules predominantly affecting lower extremities. One third of EN is idiopathic, more than half of the patients have secondary EN with etiologic factors such as infections, systemic disease, and drugs that support the hypersensitivity reaction hypothesis in pathogenesis [4,5,6]. Identifying and eliminating these etiological factors is the first step of EN treatment and may limit the recurrences of EN [1,7,8,9].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.